This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Safety and Efficacy of RCT-01 in Men and Women With Unilateral, Chronic Achilles Tendinosis (ReaCT)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Syreon Corporation
Innovacell Biotechnologie AG
Information provided by (Responsible Party):
RepliCel Life Sciences, Inc.
ClinicalTrials.gov Identifier:
NCT02330146
First received: December 12, 2014
Last updated: March 6, 2017
Last verified: March 2017
  Purpose

The primary purpose of this study is to assess the safety profile of RCT-01 injections as compared to placebo injections. This study will also measure the impact these injections will have on tendon structure and function and the symptoms of Achilles tendinosis.

28 participants will be selected for this study based on their health status, current/past medications, and ability to adhere to protocol-related requirements. Prior to entering the screening phase of the study, all potential study participants will have had to have at least 3 months of therapy for their unilateral, chronic (symptoms >6 months) Achilles tendinosis directed by a certified physiotherapist without a clinical response. At the first visit and after providing informed consent participants are evaluated against the study inclusion/exclusion criteria and provide blood samples for screening assessments (including virology). If suitable for study participation, participants will provide a biopsy from the scalp from which RCT-01 will be prepared.

Baseline evaluations of participants' overall health and tendinosis, in particular, will be performed on the day of injection. Once all baseline assessments have been completed, the tendon to be treated will be anesthetized and will receive ultrasound-guided injections of either placebo (cryomedium) or RCT-01.

All participants will return to the clinic for repeat assessments of their unilateral Achilles tendinosis and overall health at seven (7) visits over the following 6 months. Participants will also complete an eccentric training physiotherapy program under the guidance of a certified physiotherapist for two (2) months after receipt of injections. Total duration of patient participation is approximately eight (8) months.


Condition Intervention Phase
Tendinosis Tendinopathy Drug: RCT-01 Drug: Placebo Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RCT-01 in Men and Women With Unilateral, Chronic Achilles Tendinosis

Further study details as provided by RepliCel Life Sciences, Inc.:

Primary Outcome Measures:
  • Incidence of adverse events [ Time Frame: 6 months post-injection ]
    Comparison of the safety profile between RCT-01/placebo treatment groups. The safety profile is defined by the incidence, relationship to treatment, severity and seriousness of adverse events.


Secondary Outcome Measures:
  • Victorian Institute of Sport Assessment - Achilles (VISA-A) questionnaire [ Time Frame: 6 months post-injection ]
  • Visual analog scale (VAS) [ Time Frame: 6 months post-injection ]
    pain on palpation and pain on loading (running/jumping)

  • Modified Tegner Activity Scale [ Time Frame: 6 months post-injection ]
  • SF-36 questionnaire [ Time Frame: 6 months post-injection ]
    quality of life questionnaire

  • Tendon condition (appearance, biomechanics, and blood flow) [ Time Frame: 6 months post-injection ]
    Ultrasound imaging will be utilized to measure: echogenicity, hyperemia or neovascularisation, anechoic regions/intratendinous tears, intratendinous calcification, any irregularities to the cortical bone at insertion, and tendon thickness


Enrollment: 8
Study Start Date: May 2015
Estimated Study Completion Date: April 2017
Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: RCT-01
Cultured, autologous hair follicle cells suspended in cryomedium
Drug: RCT-01
Placebo Comparator: Placebo
cryomedium
Drug: Placebo

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male or female between the age of 18 and 65 years and in good health having evidence of mid-substance unilateral, chronic Achilles tendinosis confirmed by ultrasound imaging.
  2. Participant confirmation of symptoms of unilateral chronic Achilles tendinosis for at least 6 months
  3. Completion of at least three months of physiotherapy for treatment of Achilles tendinosis at the study tendon as directed by a certified physiotherapist.
  4. VISA-A score of less than 70 at Visit S1.
  5. Willingness to provide written informed consent for participation in the study, attend all study visits and complete all procedures required by this protocol.
  6. Fluent understanding of written and spoken English language
  7. Females must either be post-menopausal for at least one year, surgically sterile, or, if of childbearing potential, using highly-effective methods of birth control during the study. This method of contraception must be used at least 4 weeks prior to screening (Visit S1) and during the entire duration of the clinical trial.

Exclusion Criteria:

  1. Any prior therapeutic injections to the Achilles tendon to be studied (e.g., platelet-rich plasma, prolotherapy, dextrose, dry needling, etc) within 6 months of study Visit S1.
  2. History of Achilles tendon surgery (either tendon)
  3. Presence of enthesopathy or insertional tendinopathy in any tendons of the lower extremity, including Achilles tendons.
  4. Presence of any medical condition that influences lower extremity function (e.g. osteoarthritis, presence of any peripheral nerve involvement, etc.)
  5. Presence of seronegative arthropathies, diabetes mellitus (type I and II), elevated blood sugar, insertional arthropathies-psoriasis, iritis, inflammatory bowel syndrome, sacroiliitis, metabolic syndrome or positive test for human leukocyte antigen (HLA) B 27.
  6. Any condition that, in the investigator's opinion would impact participant safety and/or a participant's ability to complete all study related procedures. (e.g., psychiatric illness, drug addiction, alcoholism, etc.)
  7. Infection with hepatitis B or C, human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV) or syphilis
  8. Participants diagnosed with cancer with or without chemotherapy treatment
  9. Women who are pregnant or nursing
  10. Ongoing or recent (within the previous 6 months) participation in a clinical research study.
  11. Participants diagnosed having uncontrolled systemic diseases
  12. Use of any medications not permitted in the study (see Excluded Medications)
  13. Participants currently using other active treatments for tendinosis other than physiotherapy (e.g., acupuncture, trigger point therapy, chiropractic treatments, glyceryl trinitrate patches) during study or within 3 months prior to Visit 1
  14. Unresolved litigation or insurance claims (e.g., Workers Compensation, WorkSafe BC, etc.) involving the Achilles tendinopathy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02330146

Locations
Canada, British Columbia
Allan McGavin Sports Medicine Centre
Vancouver, British Columbia, Canada, V6T 1Z3
Sponsors and Collaborators
RepliCel Life Sciences, Inc.
Syreon Corporation
Innovacell Biotechnologie AG
Investigators
Principal Investigator: D R Lloyd-Smith, MDCM University of British Columbia
  More Information

Additional Information:
Responsible Party: RepliCel Life Sciences, Inc.
ClinicalTrials.gov Identifier: NCT02330146     History of Changes
Other Study ID Numbers: RCT-01-001-2014
Study First Received: December 12, 2014
Last Updated: March 6, 2017

Additional relevant MeSH terms:
Tendinopathy
Muscular Diseases
Musculoskeletal Diseases
Tendon Injuries
Wounds and Injuries

ClinicalTrials.gov processed this record on July 25, 2017